Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists

Diabetes Research and Clinical Practice

Volumn 127, Issue , 2017, Pages 224-237

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular disease; Clinical trial; DPP 4 inhibitors; GLP 1 receptor agonists; Mortality; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ACUTE PANCREATITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL OUTCOME; CLINICAL RESEARCH; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; VOMITING; COMPLICATION; OUTCOME ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RISK FACTORS;

EID: 85017278352     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2017.03.009     Document Type: Review

References (83)

1. [1] Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
2. [2] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
3. [3] Xu, J., Rajaratnam, R., Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovasc Diabetol, 16, 2017, 18.
4. [4] Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
5. [5] Goldfine, A.B., Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 359 (2008), 1092–1095.
6. [6] Smith, R.J., Goldfine, A.B., Hiatt, W.R., Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess?. Diabetes Care 39 (2016), 738–742.
7. [7] Zannad, F., Stough, W.G., Lipicky, R.J., Tamargo, J., Bakris, G.L., Borer, J.S., et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother 2 (2016), 200–205.
8. [8] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
9. [9] Garber, A.J., Abrahamson, M.J., Barzilay, J.I., Blonde, L., Bloomgarden, Z.T., Bush, M.A., et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract 22 (2016), 84–113.
10. [10] Scheen, A.J., Radermecker, R.P., Addition of incretin therapy to metformin in type 2 diabetes. Lancet 375 (2010), 1410–1412.
11. [11] Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
12. [12] Cornell, S., Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther 37 (2012), 510–524.
13. [13] Nauck, M., Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18 (2016), 203–216.
14. [14] Wang, T., Gou, Z., Wang, F., Ma, M., Zhai, S.D., Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS One, 9, 2014, e103798.
15. [15] Madsbad, S., Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med 23 (2012), 132–136.
16. [16] Scheen, A.J., Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med 23 (2012), 126–131.
17. [17] Scheen, A.J., GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?. Ann Endocrinol (Paris) 74 (2013), 515–522.
18. [18] Schernthaner, G., Schernthaner-Reiter, M.H., Schernthaner, G.H., EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents: implications for future treatment strategies in type 2 diabetes mellitus. Clin Ther 38 (2016), 1288–1298.
19. [19] Ussher, J.R., Drucker, D.J., Cardiovascular biology of the incretin system. Endocr Rev 33 (2012), 187–215.
20. [20] Ussher, J.R., Drucker, D.J., Cardiovascular actions of incretin-based therapies. Circ Res 114 (2014), 1788–1803.
21. [21] Scheen, A.J., Cardiovascular effects of gliptins. Nat Rev Cardiol 10 (2013), 73–84.
22. [22] Scheen, A.J., Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med 125 (2013), 7–20.
23. [23] Wang, T., Wang, F., Zhou, J., Tang, H., Giovenale, S., Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes Metab Res Rev 32 (2016), 843–857.
24. [24] Kim, J.Y., Yang, S., Lee, J.I., Chang, M.J., Cardiovascular effect of incretin-based therapy in patients with type 2 diabetes mellitus: systematic review and meta-analysis. PLoS One, 11, 2016, e0153502.
25. [25] Mannucci, E., Monami, M., Cardiovascular safety of incretin-based therapies in type 2 diabetes: systematic review of integrated analyses and randomized controlled trials. Adv Ther 34 (2017), 1–40.
26. [26] Scheen, A.J., A review of gliptins in 2011. Expert Opin Pharmacother 13 (2012), 81–99.
27. [27] Scheen, A.J., A review of gliptins for 2014. Exp Opin Pharmacother 16 (2015), 43–62.
28. [28] White, W.B., Baker, W.L., Cardiovascular effects of incretin-based therapies. Annu Rev Med 67 (2016), 245–260.
29. [29] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
30. [30] White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
31. [31] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
32. [32] Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., et al. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR – TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
33. [33] Cavender, M.A., Scirica, B.M., Raz, I., Gabriel Steg, P., McGuire, D.K., Leiter, L.A., et al. Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c. Am J Med 129:340 (2016), e1–e8.
34. [34] Mosenzon, O., Leibowitz, G., Bhatt, D.L., Cahn, A., Hirshberg, B., Wei, C., et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40 (2017), 69–76.
35. [35] Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
36. [36] Scott, L.J., Sitagliptin: a review in type 2 diabetes. Drugs 77 (2017), 209–224.
37. [37] McGuire, D.K., Van de Werf, F., Armstrong, P.W., Standl, E., Koglin, J., Green, J.B., et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 126–135.
38. [38] Rosenstock, J., Marx, N., Kahn, S.E., Zinman, B., Kastelein, J.J., Lachin, J.M., et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 10 (2013), 289–301.
39. [39] Marx, N., Rosenstock, J., Kahn, S.E., Zinman, B., Kastelein, J.J., Lachin, J.M., et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(R)). Diab Vasc Dis Res 12 (2015), 164–174.
40. [40] Abdelmoneim, A.S., Eurich, D.T., Light, P.E., Senior, P.A., Seubert, J.M., Makowsky, M.J., et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 17 (2015), 523–532.
41. [41] Mahmoud, A.N., Saad, M., Mansoor, H., Elgendy, A.Y., Barakat, A.F., Abuzaid, A., et al. Cardiovascular safety of incretin-based therapy for type 2 diabetes: a meta-analysis of randomized trials. Int J Cardiol 230 (2017), 324–326.
42. [42] Monami, M., Ahren, B., Dicembrini, I., Mannucci, E., Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15 (2013), 112–120.
43. [43] Cobble, M.E., Frederich, R., Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol, 11, 2012, 6.
44. [44] Iqbal, N., Parker, A., Frederich, R., Donovan, M., Hirshberg, B., Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol, 13, 2014, 33.
45. [45] White, W.B., Pratley, R., Fleck, P., Munsaka, M., Hisada, M., Wilson, C., et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 15 (2013), 668–673.
46. [46] Williams-Herman, D., Engel, S.S., Round, E., Johnson, J., Golm, G.T., Guo, H., et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord, 10, 2010, 7.
47. [47] Engel, S.S., Round, E., Golm, G.T., Kaufman, K.D., Goldstein, B.J., Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 4 (2013), 119–145.
48. [48] McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes Obes Metab 17 (2015), 1085–1092.
49. [49] Johansen, O.E., Neubacher, D., von Eynatten, M., Patel, S., Woerle, H.J., Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol, 11, 2012, 3.
50. [50] Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
51. [51] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
52. [52] Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
53. [53] Scheen, A.J., Semaglutide, a new promising glucagon-like peptide-1 receptor agonist. Lancet Diabetes Endocrinol 5 (2017), 236–238.
54. [54] Press release. Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO trial for ITCA 650, an investigational therapy for type 2 diabetes. < https://www.intarcia.com/media/press-releases/2016-may-6-cardiovascular-safety.html> [accessed Feb 24, 7].
55. [55] Holman, R.R., Bethel, M.A., George, J., Sourij, H., Doran, Z., Keenan, J., et al. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J 174 (2016), 103–110.
56. [56] Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I., Mannucci, E., Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomised clinical trials. Diabetes Obes Metab 16 (2014), 38–47.
57. [57] Monami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C.M., Iacomelli, I., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res, 2011, 2011, 215764.
58. [58] Sun, F., Yu, K., Wu, S., Zhang, Y., Yang, Z., Shi, L., et al. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract 98 (2012), 386–395.
59. [59] Wu, S., Sun, F., Zhang, Y., Yang, Z., Hong, T., Chen, Y., et al. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. J Clin Pharm Ther 39 (2014), 7–13.
60. [60] Scheen, A.J., Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. Lancet Diabetes Endocrinol 3 (2015), 667–669.
61. [61] Doggrell, S.A., After 10 years of clinical trials with liraglutide in diabetes, what do we know about its effects on clinical cardiovascular outcomes?. Rev Recent Clin Trials 10 (2015), 68–77.
62. [62] Marso, S.P., Lindsey, J.B., Stolker, J.M., House, J.A., Martinez Ravn, G., Kennedy, K.F., et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 8 (2011), 237–240.
63. [63] Fisher, M., Petrie, M.C., Ambery, P.D., Donaldson, J., Ye, J., McMurray, J.J.V., Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol 3 (2015), 697–703.
64. [64] Ferdinand, K.C., Botros, F.T., Atisso, C.M., Sager, P.T., Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol, 15, 2016, 38.
65. [65] Scheen, A.J., Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 14 (2015), 505–524.
66. [66] Schernthaner, G., Chilton, R.J., Cardiovascular risk and thiazolidinediones – what do meta-analyses really tell us?. Diabetes Obes Metab 12 (2010), 1023–1035.
67. [67] Green, J.B., Bethel, M.A., Paul, S.K., Ring, A., Kaufman, K.D., Shapiro, D.R., et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J, 166(983–9), 2013, e7.
68. [68] Bailey, C.J., Under-treatment of type 2 diabetes: causes and outcomes of clinical inertia. Int J Clin Pract 70 (2016), 988–995.
69. [69] Scheen, A.J., Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12 (2010), 648–658.
70. [70] Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
71. [71] Mannucci, E., Mosenzon, O., Avogaro, A., Analyses of results from cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis. Diabetes Care 39:Suppl. 2 (2016), S196–S204.
72. [72] Standl, E., Erbach, M., Schnell, O., Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect?. Curr Treat Options Cardiovasc Med, 16, 2014, 353.
73. [73] UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
74. [74] Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
75. [75] Scott, L.J., Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs 74 (2014), 2161–2174.
76. [76] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
77. [77] Fitchett, D., Zinman, B., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37 (2016), 1526–1534.
78. [78] Scheen, A.J., Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis. Diabetes Metab 42 (2016), 71–76.
79. [79] Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
80. [80] Scheen, A.J., GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab 43 (2017), S11–S17.
81. [81] Fitchett, D.H., Udell, J.A., Inzucchi, S.E., Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 19 (2017), 43–53.
82. [82] Standl, E., Schnell, O., McGuire, D.K., Ceriello, A., Ryden, L., Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol, 2017, 10.1016/S2213-8587(17)30033-5 Jan 25. pii: S2213-8587(17)30033-5. [Epub ahead of print].
83. [83] Schnell, O., Ryden, L., Standl, E., Ceriello, A., Group CES. Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol, 15, 2016, 139.